Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study-Reference-Cited by-同舟云学术

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study

Published:2016-02-05 Issue:5 Volume:23 Page:861-870
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Sørensen P. S.¹,Sellebjerg F.¹,Lycke J.²,Färkkilä M.³,Créange A.⁴,Lund C. G.⁵,Schluep M.⁶,Frederiksen J. L.⁷,Stenager E.⁸,Pfleger C.⁹,Garde E.¹⁰,Kinnunen E.¹¹,Marhardt K.¹²,

Affiliation:

1. Danish Multiple Sclerosis Center; Department of Neurology; Rigshospitalet; University of Copenhagen; Copenhagen Denmark

2. Department of Neurology; Sahlgrenska University Hospital; Gothenburg Sweden

3. Department of Neurology; University Central Hospital; Helsinki Finland

4. Service de Neurologie; Hôpital Henri Mondor; Université Paris Est Créteil; Créteil France

5. Department of Neurology; Oslo University Hospital; Oslo Norway

6. Service de Neurologie; Département des Neurosciences Cliniques; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland

7. Department of Neurology; Glostrup Esbjerg, Sonderborg, and Vejle, and University of Copenhagen; Copenhagen Denmark

8. Department of Neurology; Esbjerg Hospital; Sonderborg Hospital; Vejle Hospital; Odense Denmark

9. Department of Neurology; Aalborg Hospital; Aalborg Denmark

10. Danish Research Centre for Magnetic Resonance; Centre for Functional and Diagnostic Imaging and Research; Hvidovre Hospital; University of Copenhagen; Copenhagen Denmark

11. Department of Neurology; HUS Hyvinkään Hospital; Hyvinkää Finland

12. Merck Serono Global Medical Affairs; Merck GmbH; Vienna Austria

Funder

Biogen Idec

Merck Serono

Teva

Sanofi-Aventis

Novartis

RoFAR/Roche

Genzyme

Scleroseforeningen

Sundhed og Sygdom, Det Frie Forskningsråd

Sixth Framework Programme

EMD Serono

CSL Behring

LFB

GE Neuro

Octopharma

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ene.12953/fullpdf

Reference40 articles.

1. Interferon beta-1b is effective in relapsing−remitting multiple-sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial;Duquette;Neurology,1993

2. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG);Jacobs;Ann Neurol,1996

3. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis;PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group;Lancet,1998

4. High incidence of acute leukaemia in multiple sclerosis patients treated with mitoxantrone: a retrospective multicentre Italian study;Martinelli;Mult Scler,2009

5. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial;Hartung;Lancet,2002

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on combination therapies for multiple sclerosis: where are we now?;Expert Review of Neurotherapeutics;2023-12-02

2. Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis;Gut Microbes;2023-11-18

3. From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment;Biomedicines;2023-11-16

4. Long‐Term Safety Profiles of Macrolides and Tetracyclines: A Systematic Review and Meta‐Analysis;The Journal of Clinical Pharmacology;2023-10-15

5. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS);Current Reviews in Clinical and Experimental Pharmacology;2023-03